Diaceutics (DXRX) Share Price, News & Analysis

Company Overview

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

Key Stats

• Today's Range: 171 to 177
• 50-Day Range: 141 to 180
• 52-Week Range: 112.25 to 180
• Volume: 18,273 shs
• Average Volume: 164,220 shs
• Market Capitalization: £144.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: GBX 193.33
• Consensus Rating: Buy

Diaceutics Stock Analysis - MarketRank™

Diaceutics scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Diaceutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Diaceutics has a consensus price target of GBX 193.33, representing about 13.1% upside from its current price of GBX 171.

Amount of Analyst Coverage

Diaceutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Diaceutics is -95.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Diaceutics is -95.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Diaceutics has a P/B Ratio of 3.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for DXRX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Diaceutics does not currently pay a dividend.

Dividend Growth

Diaceutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.12

News Sentiment

Diaceutics has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Diaceutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 3.2 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Diaceutics in the last three months. Multiple insiders buying is a strong bullish signal.

Insider Buying vs. Insider Selling

In the past three months, Diaceutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought £450.30 in company stock and sold GBX 0 in company stock.

Percentage Held by Insiders

26.32% of the stock of Diaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

32.72% of the stock of Diaceutics is held by institutions.

Company Calendar

• Last Earnings: 9/23/2025
• Today: 5/12/2026

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: LON:DXRX
• CIK: N/A
• Web: www.diaceutics.com
• Phone: N/A
• Fax: N/A
• Employees: 151
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Diaceutics: GBX 193.33
• High Price Target: GBX 215
• Low Price Target: GBX 180
• Potential Upside/Downside: +13.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX (1.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 169.17
• P/E Growth: N/A
• Net Income: -£2.84 million
• Net Margins: -4.42%
• Pretax Margin: N/A
• Return on Equity: -3.94%
• Return on Assets: -6.06%

Debt

• Debt-to-Equity Ratio: 3.05
• Current Ratio: 3.96
• Quick Ratio: 9.92

Sales & Book Value

• Annual Sales: £34.40 million
• Price / Sales: 4.21
• Cash Flow: GBX 54.81 per share
• Price / Cash Flow: 3.12
• Book Value: GBX 45.87 per share
• Price / Book: 3.73

Miscellaneous

• Outstanding Shares: 84,629,000
• Free Float: N/A
• Market Cap: £144.72 million
• Optionable: Not Optionable
• Beta: 0.92